Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database

World Journal of Hepatology

Volumn 6, Issue 8, 2014, Pages 601-612

  Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   Koci, Ariola ^a   Caraceni, Paolo ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antimycotics; Drug safety; Drug induced hepatotoxicity; Pharmacovigilance; Spontaneous reporting systems

Indexed keywords

EID: 84906813396     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i8.601     Document Type: Article

References (59)

1. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf 2014; 13: 67-81 [PMID: 24073714 DOI: 10.1517/1474 0338.2013.828032]
2. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89: 95-106 [PMID: 24388027 DOI: 10.1016/j.mayocp.2013.09.016]
3. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-499 [PMID: 15931258 DOI: 10.1038/ nrd1750]
4. Roth RA, Ganey PE. Intrinsic versus idiosyncratic druginduced hepatotoxicity--two villains or one? J Pharmacol Exp Ther 2010; 332: 692-697 [PMID: 20019161 DOI: 10.1124/ jpet.109.162651]
5. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-620 [PMID: 19839004 DOI: 10.1002/hep.23317]
6. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009 [PMID: 18454504 DOI: 10.1002/hep.22272]
7. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388-396 [PMID: 23258593 DOI: 10.1002/hep.26208]
8. Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 2014; 42: 744-750 [PMID: 24464804 DOI: 10.1124/dmd.113.056267]
9. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815 [PMID: 21544079 DOI: 10.1038/clpt.2011.58]
10. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276 [PMID: 2254635 DOI: 10.1016/0168-8278(90)90124-A]
11. Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014; 6: 17-32 [PMID: 24653791]
12. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49: 250-257 [PMID: 19085949 DOI: 10.1002/ hep.22620]
13. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-742 [PMID: 20564754 DOI: 10.1002/hep.23696]
14. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59: 661-670 [PMID: 24037963]
15. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470 [PMID: 20170750 DOI: 10.1016/j.cgh.2010.02.008]
16. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68 [PMID: 19132805 DOI: 10.2165/00002018-200932010-00005]
17. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006; 7: 889-908 [PMID: 16981848 DOI: 10.2217/14622416.7.6.889]
18. Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmar-keting safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf 2013; 36: 183-197 [PMID: 23377696 DOI: 10.1007/s40264-013-0018-x]
19. Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis 2013; 17: 749-67, xi [PMID: 24099029 DOI: 10.1016/ j.cld.2013.07.014]
20. Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug Saf 2012; 35: 1099-1117 [PMID: 23137150]
21. Hawkins MT, Lewis JH. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol 2012; 8: 1521-1530 [PMID: 22998122 DOI: 10.15 17/17425255.2012.724060]
22. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-243 [PMID: 16552790 DOI: 10.1002/pds.1211]
23. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521 [PMID: 16083708 DOI: 10.1016/j.gastro.2005.05.006]
24. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489 [PMID: 16025496 DOI: 10.1002/hep.20800]
25. FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation (2009). Available from: URL: http://www.fda.gov/downloads/Drugs/.../Guidances/ UCM174090.pdf
26. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34: 243-252 [PMID: 21332248 DOI: 10.2165/11586600-000000000-00000]
27. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011; 66: 1431-1446 [PMID: 21586591 DOI: 10.1093/jac/dkr159]
28. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010; 65: 410-416 [PMID: 20035021 DOI: 10.1093/jac/dkp464]
29. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984; 86: 503-513 [PMID: 6319220]
30. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48: 847-852 [PMID: 10594489 DOI: 10.1046/j.1365-2125.1999.00095.x]
31. Yan JY, Nie XL, Tao QM, Zhan SY, Zhang YD. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. Biomed Environ Sci 2013; 26: 605-610 [PMID: 23895707]
32. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998; 93: 459-460 [PMID: 9517658 DOI: 10.1111/ j.1572-0241.1998.00459.x]
33. Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafineassociated hepatotoxicity. Am J Med Sci 2003; 325: 292-295 [PMID: 12792250 DOI: 10.1097/00000441-200305000-00008]
34. Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002; 112: 741-742 [PMID: 12079721 DOI: 10.1016/ S0002-9343(02)01109-9]
35. Kao WY, Su CW, Huang YS, Chou YC, Chen YC, Chung WH, Hou MC, Lin HC, Lee FY, Wu JC. Risk of oral antifungal agentinduced liver injury in Taiwanese. Br J Clin Pharmacol 2014; 77: 180-189 [PMID: 23750489 DOI: 10.1111/bcp.12178]
36. Trifirò G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, Catania MA, Salvo F, David A, Moore N, Caputi AP, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourrier-Reglat A. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18: 1176-1184 [PMID: 19757412 DOI: 10.1002/pds.1836]
37. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signaldetection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013; 93: 539-546 [PMID: 23571771 DOI: 10.1038/clpt.2013.24]
38. Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care 2012; 50: 466-478 [PMID: 22266704 DOI: 10.1097/MLR.0b013e318245a160]
39. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18: 512-518 [PMID: 19358226 DOI: 10.1002/pds.1746]
40. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010; 33: 303-314 [PMID: 20297862 DOI: 10.2165/11531850-000000000-00000]
41. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013; 36: 467-479 [PMID: 23553446 DOI: 10.1007/s40264-013-0032-z]
42. Brinker AD, Lyndly J, Tonning J, Moeny D, Levine JG, Avigan MI. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf 2013; 36: 1169-1178 [PMID: 24178291 DOI: 10.1007/s40264-013-0116-9]
43. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A. Data Mining Applications in Engineering and Medicine. InTech: Rijeka, Croatia, 2012: 267-301
44. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522 [PMID: 20486732 DOI: 10.2165/11535340-000000000-00000]
45. Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013; 369: 2525-2534 [PMID: 24369077 DOI: 10.1056/NEJMra1208937]
46. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10 [PMID: 11998548 DOI: 10.1002/pds.668]
47. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013; 50: 569-577 [PMID: 22008948 DOI: 10.1007/s00592-011-0340-7]
48. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf 2013; 36 Suppl 1: S33-S47 [PMID: 24166222 DOI: 10.1007/s40264-013-0097-8]
49. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, Fourrier-Réglat A, Molokhia M, Patadia V, van der Lei J, Sturkenboom M, Trifirò G. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf 2013; 36: 13-23 [PMID: 23315292 DOI: 10.1007/s40264-012-0002-x]
50. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18: 427-436 [PMID: 19358225 DOI: 10.1002/pds.1742]
51. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36: 491-503 [PMID: 23620168 DOI: 10.1007/ s40264-013-0048-4]
52. NEVAXAR. EMA: procedural steps taken and scientific information after the authorisation (2010). Available from: URL: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_Procedural_steps_taken_and_sc ientific_information_after_authorisation/human/000690/ WC500027709.pdf
53. NEVAXAR. FDA: Labeling Revision (2010). Available from: URL: http://www.accessdata.fda.gov/drugsatfda_docs/ appletter/2012/021923Origs013ltr.pdf
54. Petronijevic M, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. J Clin Pharmacol 2013; 53: 435-443 [PMID: 23440959 DOI: 10.1002/jcph.3]
55. Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol 2009; 67: 88-98 [PMID: 19076158 DOI: 10.1111/j.1365-2125.2008.03319.x]
56. Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, Bennie M, Barbui C, Wettermark B, Sturkenboom M, De Ponti F. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 2013; 8: e81208 [PMID: 24278396 DOI: 10.1371/ journal.pone.0081208]
57. Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother 2010; 65: 769-774 [PMID: 20142264 DOI: 10.1093/jac/dkq023]
58. Adriaenssens N, Coenen S, Versporten A, Goossens H. Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insight. Int J Antimicrob Agents 2013; 42: 466-470 [PMID: 23993932 DOI: 10.1016/j.ijantimicag. 2013.07.004]
59. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect 2012; 18: E389-E395 [PMID: 22827696 DOI: 10.1111/j.1469-0691.2012.03973.x]